Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Deferred Revenue (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Current Deferred Revenue for 4 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue fell 99.13% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Sep 2025, down 99.13%, and an annual FY2024 reading of $95.1 million, up 22.17% over the prior year.
  • Current Deferred Revenue was $1.0 million for Q3 2025 at Atara Biotherapeutics, down from $1.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $123.2 million in Q1 2024 and bottomed at $1.0 million in Q3 2025.
  • Average Current Deferred Revenue over 4 years is $47.5 million, with a median of $16.0 million recorded in 2025.
  • The sharpest move saw Current Deferred Revenue soared 1140.97% in 2024, then tumbled 99.13% in 2025.
  • Year by year, Current Deferred Revenue stood at $85.0 million in 2022, then fell by 8.43% to $77.8 million in 2023, then grew by 22.17% to $95.1 million in 2024, then tumbled by 98.94% to $1.0 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ATRA at $1.0 million in Q3 2025, $1.6 million in Q2 2025, and $16.0 million in Q1 2025.